Uniqure NV (QURE)

NASDAQ
14.12
-0.08(-0.56%)
  • Volume:
    431,985
  • Day's Range:
    13.77 - 14.58
  • 52 wk Range:
    12.52 - 38.80

QURE Overview

Prev. Close
14.2
Day's Range
13.77-14.58
Revenue
525.34M
Open
14.23
52 wk Range
12.52-38.8
EPS
6.89
Volume
431,985
Market Cap
658.66M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
515,080
P/E Ratio
2.06
Beta
1.12
1-Year Change
-57.9%
Shares Outstanding
46,647,620
Next Earnings Date
Aug 03, 2022
What is your sentiment on Uniqure NV?
or
Market is currently closed. Voting is open during market hours.

Uniqure NV News

Uniqure NV Analysis

Uniqure NV Company Profile

Uniqure NV Company Profile

Employees
463

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson’s disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer’s disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyBuySellStrong Sell
Technical IndicatorsStrong SellStrong BuyStrong BuySellStrong Sell
SummarySellStrong BuyStrong BuySellStrong Sell
  • Company keeps getting positive results in their experiments, yet the price keeps falling. Talk about manipulation.
    0
    • crazy 7 days stock in the same price Jesus
      0
      • 10851397
        0
        • Getting to worthless! Jan, 2017 is the aim?
          1